PURPOSE: PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis. METHODS: We identified 16 patients from 8,819 restaging FDG PET/CT scans with suspicion of or biopsy-proven fat necrosis on PET/CT. RESULTS: All patients had NHL and demonstrated focal FDG-avid nodular change on CT with density higher than that of fat but lower than that of soft tissue. Histological confirmation was obtained in eight patients, with high GLUT-1 staining between necrotic tissue and organizing fat necrosis evident. Uptake resolved in four patients, and surveillance was continuing in four without relapse. CONCLUSION: Although rare, identification of fat necrosis in patients with a solitary FDG-avid nodule after therapy is important and may lead to the avoidance of unnecessary interventions or treatment. Specific features on CT aid identification, whilst follow-up imaging can be helpful as the metabolic abnormality regresses with time.
PURPOSE: PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis. METHODS: We identified 16 patients from 8,819 restaging FDG PET/CT scans with suspicion of or biopsy-proven fat necrosis on PET/CT. RESULTS: All patients had NHL and demonstrated focal FDG-avid nodular change on CT with density higher than that of fat but lower than that of soft tissue. Histological confirmation was obtained in eight patients, with high GLUT-1 staining between necrotic tissue and organizing fat necrosis evident. Uptake resolved in four patients, and surveillance was continuing in four without relapse. CONCLUSION: Although rare, identification of fat necrosis in patients with a solitary FDG-avid nodule after therapy is important and may lead to the avoidance of unnecessary interventions or treatment. Specific features on CT aid identification, whilst follow-up imaging can be helpful as the metabolic abnormality regresses with time.
Authors: Markus Joerger; Dominique F Nuessli; Samuel Henz; Wolfgang Zaunbauer; Thomas Cerny; Sergio B Cogliatti; Silke Gillessen Journal: Onkologie Date: 2008-09-23
Authors: Ashley P Ng; Andrew Wirth; John F Seymour; Michael Lee; Annette Hogg; Henry Januszewicz; Max Wolf; H Miles Prince; Michael Macmanus; Rodney J Hicks Journal: Leuk Lymphoma Date: 2007-03
Authors: Anna Maria De Gaetano; Maria Lucia Calcagni; Vittoria Rufini; Anna Lia Valentini; Benedetta Gui; Alessandro Giordano; Lorenzo Bonomo Journal: Abdom Imaging Date: 2009-11
Authors: Shelby L Kubicki; Michael L Richardson; Thomas Martin; Eric Rohren; Wei Wei; Behrang Amini Journal: Skeletal Radiol Date: 2014-10-07 Impact factor: 2.199
Authors: Christian Furth; Ingo G Steffen; Anne S Erdrich; Patrick Hundsdoerfer; Juri Ruf; Günter Henze; Stefan Schönberger; Holger Amthauer; Hubertus Hautzel Journal: EJNMMI Res Date: 2013-10-18 Impact factor: 3.138